|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12N 9/22 | (2006.01) |
| C07K2319/81 | (2013.01) | ||
| A61K 38/00 | (2006.01) | ||
| A61K 38/00 | (2013.01) | ||
| C12N 9/22 | (2013.01) |
| (11) | Number of the document | 3504327 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17844412.1 |
| Date of filing the European patent application | 2017-08-24 | |
| (97) | Date of publication of the European application | 2019-07-03 |
| (45) | Date of publication and mention of the grant of the patent | 2021-10-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2017/048409 |
| Date | 2017-08-24 |
| (87) | Number | WO 2018/039448 |
| Date | 2018-03-01 |
| (30) | Number | Date | Country code |
| 201662378978 P | 2016-08-24 | US | |
| 201762443981 P | 2017-01-09 | US |
| (72) |
MILLER, Jeffrey C. , US
REBAR, Edward J. , US
|
| (73) |
Sangamo Therapeutics, Inc. ,
7000 Marina Blvd, Brisbane, CA 94005,
US
|
| (54) | ENGINEERED TARGET SPECIFIC NUCLEASES |
| ENGINEERED TARGET SPECIFIC NUCLEASES |